Adicet Bio (ACET) Current Assets (2017 - 2026)

Adicet Bio's Current Assets history runs 10 years deep, the most recent figure standing at $140.1 million for Q1 2026.

• In Q1 2026, Current Assets fell 8.79% year-over-year to $140.1 million; the TTM figure through Mar 2026 stood at $140.1 million (down 8.79% YoY), while the FY2025 annual figure was $160.9 million, down 10.66% from the prior year.
• Current Assets for Q1 2026 stood at $140.1 million, down from $160.9 million in the prior quarter.
• The five-year high for Current Assets was $285.7 million in Q3 2022, with the low at $106.5 million in Q3 2025.
• The 5-year median for Current Assets is $206.3 million (2024), against an average of $202.2 million.
• The sharpest annual moves came in 2022 and 2025: Current Assets soared 43.57% in 2022, then slumped 48.38% in 2025.
• Adicet Bio's Current Assets stood at $261.0 million in 2022, then slumped by 37.84% to $162.3 million in 2023, then increased by 11.01% to $180.1 million in 2024, then fell by 10.66% to $160.9 million in 2025, then decreased by 12.96% to $140.1 million in 2026.
• Business Quant data shows ACET's Current Assets at $140.1 million in Q1 2026, $160.9 million in Q4 2025, and $106.5 million in Q3 2025.